ZnPP‐laden nanoparticles improve glucose homeostasis and chronic inflammation during obesity

Abstract

AbstractBackground and PurposeChronic inflammation plays a pivotal role in the development of Type 2 diabetes mellitus (T2DM). Previous studies have shown that haem oxygenase‐1 (HO‐1) plays a proinflammatory role during metabolic stress, suggesting that HO‐1 inhibition could be an effective strategy to treat T2DM. However, the application of HO‐1 inhibitors is restricted due to solubility‐limited bioavailability. In this study, we encapsulated the HO‐1 inhibitor, zinc protoporphyrin IX (ZnPP), within nanoparticles and investigated their role in regulating glucose homeostasis and chronic inflammation during obesity.Experimental ApproachWe delivered DMSO‐dissolved ZnPP (DMSO‐ZnPP) and ZnPP‐laden nanoparticles (Nano‐ZnPP) to diet‐induced obese male mice for 6 weeks. Glucose and insulin tolerance tests were carried out, liver and adipose tissue gene expression profiles analysed, and systemic inflammation analysed using flow cytometry.Key ResultsNanoparticles significantly increased the delivery efficiency of ZnPP in both cells and mice. In mice with diet‐induced obesity, inhibition of HO‐1 by Nano‐ZnPP significantly decreased adiposity, increased insulin sensitivity, and improved glucose tolerance. Moreover, Nano‐ZnPP treatment attenuated both local and systemic inflammatory levels during obesity. Mechanistically, Nano‐ZnPP significantly attenuated glucagon, TNF, and fatty acid synthesis signalling pathways in the liver. In white adipose tissue, the oxidative phosphorylation signalling pathway was enhanced and the inflammation signalling pathway diminished by Nano‐ZnPP. Our results show that Nano‐ZnPP has better effects on the improvement of glucose homeostasis and attenuation of chronic inflammation, than those of DMSO‐dissolved ZnPP.Conclusions and ImplicationsThese findings indicate that ZnPP‐laden nanoparticles are potential therapeutic agents for treating T2DM.